HMGB1 in Hormone-Related Cancer: a Potential Therapeutic Target

被引：0
作者：
Madhuwanti Srinivasan
Souresh Banerjee
Allison Palmer
Guoxing Zheng
Aoshuang Chen
Maarten C. Bosland
André Kajdacsy-Balla
Ramaswamy Kalyanasundaram
Gnanasekar Munirathinam
机构：
[1] University of Illinois,Department of Biomedical Sciences
[2] College of Medicine,Department of Pathology
[3] University of Illinois at Chicago,undefined
[4] University of Illinois Cancer Center,undefined
来源：
Hormones and Cancer | 2014年 / 5卷
关键词：
Ethyl Pyruvate; Clear Cell Renal Cell Carcinoma; Glycyrrhetinic Acid; Cervical Squamous Cell Carcinoma; HMGB1 Level;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
High-mobility group box 1 (HMGB1) is a dynamic nuclear protein participating in transcription, chromatin remodelling, and DNA recombination and repair processes. Accumulating evidence indicates that its function now extends beyond the nucleus, notably its extracellular role in inflammation. HMGB1 is implicated as a late mediator of sepsis and is also believed to promote atherosclerosis and other inflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosus. Interestingly, deregulation of HMGB1 is shown to be associated with the hallmarks of cancer development. Moreover, several clinical studies have shown that HMGB1 is a promising biomarker for a variety of cancer types. In this review, we provide novel insights into the role and mechanisms of HMGB1, in particular, to hormone-related cancers and its potential to serve as a therapeutic target.
引用
收藏
页码：127 / 139
页数：12
相关论文
共 746 条
[91]  
Chen J(2012)The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia Proc Natl Acad Sci U S A 109 7031-2289
[92]  
Hong M(2010)HMGB1 release and redox regulates autophagy and apoptosis in cancer cells Oncogene 29 5299-1461
[93]  
Luther T(2012)Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma J Cancer Res Clin Oncol 138 11-3301
[94]  
Henle T(2013)Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models J Immunother 36 102-217
[95]  
Kloting I(2002)Immunotherapy of metastatic renal cell cancer Cancer Control 9 293-399
[96]  
Morcos M(2012)Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression Cancer Res 72 2791-607
[97]  
Hofmann M(2012)Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity Autophagy 8 1264-980
[98]  
Tritschler H(2012)HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells Oncol Rep 28 2285-258
[99]  
Weigle B(2010)Cross-talk between NO and HMGB1 in lymphocytic thyroiditis and papillary thyroid cancer Oncol Rep 24 1455-441
[100]  
Kasper M(2012)Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma Cancer Res 72 3290-347
567891011121314